PE20091024A1 - Anticuerpos monoclonales que se unen a anexelekto y sus usos - Google Patents

Anticuerpos monoclonales que se unen a anexelekto y sus usos

Info

Publication number
PE20091024A1
PE20091024A1 PE2008001927A PE2008001927A PE20091024A1 PE 20091024 A1 PE20091024 A1 PE 20091024A1 PE 2008001927 A PE2008001927 A PE 2008001927A PE 2008001927 A PE2008001927 A PE 2008001927A PE 20091024 A1 PE20091024 A1 PE 20091024A1
Authority
PE
Peru
Prior art keywords
anexelekto
monoclonal antibodies
antibodies binding
axl
cdr2
Prior art date
Application number
PE2008001927A
Other languages
English (en)
Inventor
Takehisa Kitazawa
Tsukasa Suzuki
Shigehisa Nagahashi
Hajime Miyamoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40638811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20091024A1 publication Critical patent/PE20091024A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDO A UN ANTICUERPO MONOCLONAL QUIMERICO O HUMANIZADO, QUE SE UNE A FND1 DE AXL, QUE COMPRENDE CADENAS PESADAS CDR1, CDR2 Y CDR3 DE SEQ ID Nº 4, 5 Y 6 RESPECTIVAMENTE Y CADENAS LIVIANAS CDR1, CDR2 Y CDR3 DE SEQ ID Nº 8, 9 Y 10 RESPECTIVAMENTE, AMBAS CON SUSTITUCION, SUPRESION, INSERCION Y/O ADICION DE UNO O MAS AMINOACIDOS. DICHO ANTICUERPO INHIBE LA ANGIOGENESIS, SUPRIME EL CRECIMIENTO DE CELULAS CANCEROSAS, INDUCEN E INHIBEN LA FOSFORILACION DE AXL Y ES ANTICANCERIGENO
PE2008001927A 2007-11-15 2008-11-14 Anticuerpos monoclonales que se unen a anexelekto y sus usos PE20091024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007297168 2007-11-15

Publications (1)

Publication Number Publication Date
PE20091024A1 true PE20091024A1 (es) 2009-08-12

Family

ID=40638811

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001927A PE20091024A1 (es) 2007-11-15 2008-11-14 Anticuerpos monoclonales que se unen a anexelekto y sus usos

Country Status (18)

Country Link
US (2) US9175091B2 (es)
EP (2) EP2228392A4 (es)
JP (2) JP5554993B2 (es)
KR (1) KR101568051B1 (es)
CN (1) CN101918452A (es)
AR (1) AR069333A1 (es)
AU (1) AU2008321835B2 (es)
BR (1) BRPI0820543A2 (es)
CA (1) CA2706549A1 (es)
CL (1) CL2008003416A1 (es)
IL (1) IL205545A0 (es)
MX (1) MX2010005397A (es)
PE (1) PE20091024A1 (es)
RU (1) RU2559530C2 (es)
SG (1) SG188134A1 (es)
TW (1) TW200936160A (es)
WO (1) WO2009063965A1 (es)
ZA (1) ZA201003496B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
EP2228392A4 (en) 2007-11-15 2012-05-02 Chugai Pharmaceutical Co Ltd MONOCLONAL ANTIBODY CAPABLE OF BINDING TO AN UNCONTROLLED GENE (ANEXELEKTO) AND USE THEREOF
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
BRPI1011145A2 (pt) 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
TW201204388A (en) 2010-06-18 2012-02-01 Genentech Inc Anti-Axl antibodies and methods of use
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2723376B1 (en) * 2011-06-22 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US20150252370A1 (en) * 2014-03-04 2015-09-10 Academia Sinica Use of atx inhibitors for treatment or prevention of influenza virus a infections
GB201410826D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
CN107074948B (zh) 2014-07-11 2022-01-28 根马布股份公司 结合axl的抗体
CA2959141A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
JP6864953B2 (ja) * 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Axlに対するヒトモノクローナル抗体
EP3233119A2 (en) 2014-12-18 2017-10-25 Bergen Teknologioverforing AS Anti-axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
PT3319993T (pt) 2015-07-10 2020-04-22 Genmab As Conjugados de anticorpo-fármaco específicos de axl para tratamento de cancro
EP3385587B1 (en) * 2015-12-03 2023-08-02 Mitsubishi Electric Corporation Elastic body for closure, air conditioning device, and closure method
WO2017121867A1 (en) 2016-01-13 2017-07-20 Genmab A/S Formulation for antibody and drug conjugate thereof
US11254742B2 (en) 2016-05-13 2022-02-22 Bioatla, Inc. Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
BR112019014615A2 (pt) 2017-01-18 2020-06-02 F1 Oncology, Inc. Receptores de antígeno quimérico contra axl ou ror2 e métodos de uso dos mesmos
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CA3095986A1 (en) 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
US20220273809A1 (en) 2019-07-19 2022-09-01 Genmab A/S Axl antibody-drug conjugates for use in treating cancer
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
EP4110824A1 (en) 2020-02-28 2023-01-04 Symphogen A/S Anti-axl antibodies and compositions
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
IL297132A (en) 2020-04-08 2022-12-01 Bergenbio Asa axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN116063535B (zh) * 2022-09-14 2023-09-26 北京市疾病预防控制中心 一种抗体或其抗原结合片段及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR900701846A (ko) * 1988-09-28 1990-12-04 원본미기재 세포간 점착분자 및 이의 결합 리간드
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US5468624A (en) * 1993-07-02 1995-11-21 Board Of Regents, The University Of Texas System Cell lysis activity of a modified fragment of the glucocorticoid receptor
JPH09506250A (ja) * 1993-11-23 1997-06-24 ジェネンテク,インコーポレイテッド Rseと命名される蛋白チロシンキナーゼ
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
EP1563094A4 (en) 2002-10-29 2007-04-25 Rigel Pharmaceuticals Inc MODULATORS OF ANGIOGENESIS AND TUMORIGENESIS
EP1572103A4 (en) * 2002-11-15 2008-02-13 Centocor Inc ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS
WO2005048822A2 (en) * 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
CA2621503C (en) 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
EP1789435B1 (en) * 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
RU2008135318A (ru) * 2006-02-01 2010-03-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии неопластических или инфекционных заболеваний
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
SG10201405835TA (en) 2007-11-12 2014-10-30 U3 Pharma Gmbh Axl antibodies
EP2228392A4 (en) 2007-11-15 2012-05-02 Chugai Pharmaceutical Co Ltd MONOCLONAL ANTIBODY CAPABLE OF BINDING TO AN UNCONTROLLED GENE (ANEXELEKTO) AND USE THEREOF
BRPI1011145A2 (pt) * 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl

Also Published As

Publication number Publication date
KR101568051B1 (ko) 2015-11-10
IL205545A0 (en) 2010-12-30
WO2009063965A1 (ja) 2009-05-22
EP2228392A1 (en) 2010-09-15
CN101918452A (zh) 2010-12-15
MX2010005397A (es) 2010-10-04
US20110044984A1 (en) 2011-02-24
JP5554993B2 (ja) 2014-07-23
BRPI0820543A2 (pt) 2015-06-16
CL2008003416A1 (es) 2009-10-30
TW200936160A (en) 2009-09-01
JP2014224116A (ja) 2014-12-04
JPWO2009063965A1 (ja) 2011-03-31
AU2008321835B2 (en) 2014-11-20
KR20100097688A (ko) 2010-09-03
AR069333A1 (es) 2010-01-13
AU2008321835A1 (en) 2009-05-22
RU2559530C2 (ru) 2015-08-10
CA2706549A1 (en) 2009-05-22
SG188134A1 (en) 2013-03-28
EP2853544A1 (en) 2015-04-01
US20160053019A1 (en) 2016-02-25
ZA201003496B (en) 2011-08-31
RU2010123916A (ru) 2011-12-20
EP2228392A4 (en) 2012-05-02
US9175091B2 (en) 2015-11-03

Similar Documents

Publication Publication Date Title
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
CO6251371A2 (es) Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
PE20191546A1 (es) Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
RS54624B1 (en) MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
PE20241349A1 (es) Anticuerpos de union a cd3
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
BRPI0811526A2 (pt) uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
NZ600262A (en) Anti-her3 antibodies and uses thereof

Legal Events

Date Code Title Description
FC Refusal